P A Gurbel

Summary

Affiliation: Sinai Hospital of Baltimore
Country: USA

Publications

  1. ncbi request reprint Clopidogrel resistance: implications for coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Curr Pharm Des 12:1261-9. 2006
  2. ncbi request reprint Drug insight: Clopidogrel nonresponsiveness
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Nat Clin Pract Cardiovasc Med 3:387-95. 2006
  3. ncbi request reprint The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
    Kevin P Bliden
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 52:531-3. 2008
  4. doi request reprint Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting
    Mark J Antonino
    Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
    Am J Cardiol 103:1546-50. 2009
  5. ncbi request reprint Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin
    K P Bliden
    Paul A Gurbel, MD, Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Sinai Hospital of Baltimore, 2401 W Belvedere Ave, Baltimore, MD 21215, USA, Tel 1 410 601 9600, Fax 1 410 601 9601, E mail
    Thromb Haemost 112:323-31. 2014
  6. ncbi request reprint Update: Acute coronary syndromes (V). Personalized antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, United States Electronic address
    Rev Esp Cardiol (Engl Ed) 67:480-7. 2014
  7. pmc Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA
    Drug Healthc Patient Saf 2:233-40. 2010
  8. ncbi request reprint Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes
    Young Hoon Jeong
    Paul A Gurbel, MD, Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 W Belvedere Ave, Baltimore, MD 21215, USA, Tel 1 410 601 9600, Fax 1 410 601 9601, E mail
    Thromb Haemost 111:713-24. 2014
  9. doi request reprint The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    J Am Coll Cardiol 62:505-12. 2013
  10. doi request reprint Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD, USA
    Am Heart J 165:176-82. 2013

Collaborators

Detail Information

Publications111 found, 100 shown here

  1. ncbi request reprint Clopidogrel resistance: implications for coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Curr Pharm Des 12:1261-9. 2006
    ..The mechanisms of the response variability to clopidogrel remain incompletely defined. The contribution of intra- and extracellular pathways are under investigation...
  2. ncbi request reprint Drug insight: Clopidogrel nonresponsiveness
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Nat Clin Pract Cardiovasc Med 3:387-95. 2006
    ..The aim of this article is to provide a comprehensive and current review of clopidogrel response variability and nonresponsiveness...
  3. ncbi request reprint The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
    Kevin P Bliden
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 52:531-3. 2008
    ..The purpose of this study was to examine the effect of cigarette smoking on the platelet response to clopidogrel...
  4. doi request reprint Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting
    Mark J Antonino
    Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
    Am J Cardiol 103:1546-50. 2009
    ..04) and between specific inflammation markers (p < or = 0.02). In conclusion, in addition to markedly lowering platelet reactivity to adenosine diphosphate, long-term clopidogrel therapy is associated with an anti-inflammatory effect...
  5. ncbi request reprint Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin
    K P Bliden
    Paul A Gurbel, MD, Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Sinai Hospital of Baltimore, 2401 W Belvedere Ave, Baltimore, MD 21215, USA, Tel 1 410 601 9600, Fax 1 410 601 9601, E mail
    Thromb Haemost 112:323-31. 2014
    ..Elevated 11-dh TxB2 was associated with a prothrombotic state indicated by high TIP-FCS. Our data suggest that measurement of urinary 11-dTxB2 may be a useful method to optimise statin dosing in order to reduce thrombotic risk. ..
  6. ncbi request reprint Update: Acute coronary syndromes (V). Personalized antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, United States Electronic address
    Rev Esp Cardiol (Engl Ed) 67:480-7. 2014
    ..In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy. ..
  7. pmc Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA
    Drug Healthc Patient Saf 2:233-40. 2010
    ..The data regarding pharmacologic and clinical interactions between PPI and clopidogrel therapies are herein examined and treatment strategies are provided...
  8. ncbi request reprint Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes
    Young Hoon Jeong
    Paul A Gurbel, MD, Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 W Belvedere Ave, Baltimore, MD 21215, USA, Tel 1 410 601 9600, Fax 1 410 601 9601, E mail
    Thromb Haemost 111:713-24. 2014
    ..Combining the measurements of platelet aggregation and platelet-fibrin clot strength may enhance post-PCI risk stratification and deserves further study. ..
  9. doi request reprint The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    J Am Coll Cardiol 62:505-12. 2013
    ..The goal of this study was to evaluate the effect of smoking on the pharmacokinetics and pharmacodynamics (PD) of clopidogrel and prasugrel therapy...
  10. doi request reprint Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD, USA
    Am Heart J 165:176-82. 2013
    ..Spaced administration of a clopidogrel and a single-tablet formulation of aspirin and immediate-release omeprazole (PA32540) was considered as an alternative that might reduce this potential pharmacodynamic interaction...
  11. doi request reprint Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study
    P A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
    Clin Pharmacol Ther 90:860-6. 2011
    ..Spacing the administration of PA32540 and clopidogrel lessens the interaction observed with synchronous administration; PA32540 administration with clopidogrel may be associated with a different antiplatelet profile...
  12. doi request reprint Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel
    Young Hoon Jeong
    Sinai Center for Thrombosis Research, Cardiac Catherization Laboratories, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Expert Opin Pharmacother 13:1771-96. 2012
    ..Prasugrel therapy is recommended in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI)...
  13. doi request reprint Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Thromb Haemost 108:12-20. 2012
    ..Therefore, futher studies are needed to delineate the role of platelet function testing across the spectrum of symptomatic coronary artery disease...
  14. ncbi request reprint Platelet activation in myocardial ischemic syndromes
    Paul A Gurbel
    John Hopkins University School of Medicine, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Rev Cardiovasc Ther 2:535-45. 2004
    ....
  15. ncbi request reprint Prasugrel, a third generation thienopyridine and potent platelet inhibitor
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Curr Opin Investig Drugs 9:324-36. 2008
    ..The companies were expected to launch the drug in the US by the end of 2008...
  16. ncbi request reprint The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 45:1392-6. 2005
    ..We determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) and high post-treatment platelet aggregation (post-PA)...
  17. doi request reprint Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Blood Coagul Fibrinolysis 19:268-75. 2008
    ..Point-of-service measurements of platelet-fibrin clot characteristics may lead to more intensified antithrombotic therapy and reduced mortality in selected patients...
  18. ncbi request reprint Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 111:1153-9. 2005
    ..Moreover, limited information is available on the antiplatelet pharmacodynamics of a 300-mg versus a 600-mg clopidogrel loading dose, and the comparative effect of eptifibatide with these regimens is unknown...
  19. ncbi request reprint The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Avenue, Baltimore, MD 21215, USA
    Thromb Res 112:9-12. 2003
    ..Marked variability in activation and reactivity were observed despite aspirin therapy...
  20. ncbi request reprint The platelet-related effects of tenecteplase versus alteplase versus reteplase
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Blood Coagul Fibrinolysis 16:1-7. 2005
    ..These findings may be directly relevant to the effect of alteplase on reperfusion and to future studies using combined platelet inhibitors and thrombolytic therapy...
  21. doi request reprint Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Department of Medicine, Sinai Hospital, Baltimore, Maryland 21215, USA
    Platelets 19:595-604. 2008
    ..The study is a step towards a personalized medicine approach to guide the intensity of antiplatelet therapy...
  22. ncbi request reprint Antiplatelet treatment of cardiovascular disease: a translational research perspective
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
    Pol Arch Med Wewn 118:289-97. 2008
    ..Finally, based on the current evidence platelet reactivity may become a standard of care risk factor measured in all patients with cardiovascular disease...
  23. ncbi request reprint Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Platelets 15:95-9. 2004
    ..These finding suggest insufficient platelet inhibition. The clinical importance of these findings should be further investigated to establish the potential link between insufficient platelet inhibition, stent thrombosis, and restenosis...
  24. ncbi request reprint Diagnostics for aspirin resistance
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Mol Diagn Ther 12:55-6. 2008
  25. ncbi request reprint Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 155:56-61. 2008
    ....
  26. ncbi request reprint Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 48:2186-91. 2006
    ..This study was performed to compare the effects of antiplatelet regimens on early inflammation and cardiac marker release after elective stenting...
  27. ncbi request reprint Clopidogrel resistance?
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Thromb Res 120:311-21. 2007
    ..Small scale investigations have suggested that nonresponsiveness may be associated with a heightened risk for adverse clinical events. The above findings have stimulated a close examination of clopidogrel metabolism...
  28. ncbi request reprint Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Thromb Res 121:107-15. 2007
    ..The P2Y12 reactivity ratio (PRR) determined by vasodilator-stimulated phosphoprotein phosphorylation levels has been used to indicate the extent of P2Y(12) blockade...
  29. ncbi request reprint Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 115:3156-64. 2007
    ..Our primary aim was to determine the degree of platelet aspirin responsiveness in patients, as measured by commonly used methods, and to study the relation of aspirin dose to platelet inhibition...
  30. ncbi request reprint Aspirin and clopidogrel resistance: consideration and management
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Interv Cardiol 19:439-48. 2006
    ..A higher aspirin dose and strict compliance to therapy may overcome the occurrence of "aspirin resistance" in selected patients. A higher clopidogrel dose may be considered in patients exhibiting clopidogrel nonresponsiveness...
  31. ncbi request reprint Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Building, Baltimore, MD 21215, USA
    Thromb Res 119:563-70. 2007
    ..However, the effect of the clopidogrel loading dose on the rate of thrombin-induced platelet-fibrin clot formation is unknown in this patient population...
  32. ncbi request reprint Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland 21215, USA
    Am J Cardiol 100:18M-25M. 2007
    ..Large prospective studies designed to identify which patients are at risk for stent thrombosis on the basis of platelet function testing are under way and may eventually lead to personalized antithrombotic therapy...
  33. ncbi request reprint Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1827-32. 2005
    ..We investigated whether patients who suffered subacute stent thrombosis (SAT) have higher post-treatment reactivity than those who do not encounter stent thrombosis...
  34. ncbi request reprint Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1820-6. 2005
    ..We investigated the relation of high ex vivo platelet reactivity, rapid fibrin generation, and high thrombin-induced clot strength to postdischarge ischemic events in patients undergoing percutaneous coronary intervention (PCI)...
  35. ncbi request reprint A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Platelets 14:481-3. 2003
  36. ncbi request reprint The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    J Interv Cardiol 21:S10-7. 2008
    ..In the highest risk patients with elevated cardiac biomarkers indicative of myonecrosis, current guidelines support the use of early therapy with glycoprotein IIb/IIIa inhibition, aspirin, and clopidogrel...
  37. ncbi request reprint Platelet activation after stenting with heparin-coated versus noncoated stents
    Paul A Gurbel
    Sinai Hospital, Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 146:E10. 2003
    ..However, reduced platelet activation has never been demonstrated in humans. The purpose of the current study was to investigate the effect of heparin coating on platelet activation after coronary artery stenting...
  38. doi request reprint Genotyping: one piece of the puzzle to personalize antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Sinai Hospital of Baltimore, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 56:112-6. 2010
    ..Prospective clinical trials to test new algorithms for optimal personalized antiplatelet therapy are needed to provide the evidence base required for the routine adoption of genotyping into clinical practice...
  39. pmc Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 160:346-54. 2010
    ..Ex vivo platelet function measurements may facilitate risk stratification and personalized antiplatelet therapy...
  40. doi request reprint Ticagrelor for the treatment of arterial thrombosis
    Paul A Gurbel
    Sinai Hospital of Baltimore, Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Expert Opin Pharmacother 11:2251-9. 2010
    ..Thus, it is both appropriate and timely to review available data and provide a comprehensive review of ticagrelor...
  41. doi request reprint Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Thromb Haemost 106:248-52. 2011
    ..However, in the absence of a large-scale prospective clinical trial, routine platelet function monitoring and modification of timing of surgery based on platelet function monitoring are currently not recommended...
  42. doi request reprint Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Thromb Haemost 106:265-71. 2011
    ..Large-scale trials are ongoing that will investigate the role of personalised antiplatelet therapy in the PCI patient...
  43. pmc The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 161:598-604. 2011
    ..Because both predict cardiovascular events with similar risk ratios, CYP2C19 genotyping and HPR may provide complementary information to stratify risk and personalized DAPT in stented patients than either alone...
  44. doi request reprint Vorapaxar: a novel protease-activated receptor-1 inhibitor
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Expert Opin Investig Drugs 20:1445-53. 2011
    ..Platelet activation and reactivity are pivotal for both acute and chronic atherothrombotic event occurrences...
  45. ncbi request reprint Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215 5271, USA
    Am Heart J 145:239-47. 2003
    ..We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients...
  46. ncbi request reprint The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
    Platelets 20:97-104. 2009
    ..Larger studies are required to solidify these observations and their clinical relevance...
  47. doi request reprint Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Baltimore, MD 21215, USA
    Circulation 121:1188-99. 2010
    ..The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they switch agents are unknown...
  48. ncbi request reprint Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Am J Cardiol 90:312-5. 2002
  49. doi request reprint Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 120:2577-85. 2009
    ..This is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using the PLATO (PLATelet inhibition and patient Outcomes) trial loading dose (180 mg) with a high loading dose (600 mg) of clopidogrel...
  50. ncbi request reprint Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy)
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Thromb Thrombolysis 14:213-9. 2002
    ..The effect of eptifibatide on these receptors was investigated in a substudy of the EARLY Trial...
  51. ncbi request reprint Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Paul A Gurbel, MD Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Curr Treat Options Cardiovasc Med 11:22-32. 2009
    ..T.E.N.T. Thrombosis Study and future research will likely support the current concepts and lead to personalized treatment regimens that will optimize antiplatelet therapy...
  52. ncbi request reprint Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 107:2908-13. 2003
    ..Clopidogrel is administered to prevent stent thrombosis; however, the uniformity of platelet inhibition after treatment and the influence of pretreatment reactivity on drug response have not been described...
  53. ncbi request reprint Durability of platelet inhibition by clopidogrel
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Am J Cardiol 91:1123-5. 2003
  54. ncbi request reprint Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to
    Paul A Gurbel
    Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    J Am Coll Cardiol 53:648-57. 2009
    ..The secondary aim was to study the relation of platelet aggregation and TIP-FCS to the occurrence of periprocedural infarction...
  55. doi request reprint Recent developments in clopidogrel pharmacology and their relation to clinical outcomes
    Paul A Gurbel
    Sinai Hospital of Baltimore, Sinai Center for Thrombosis Research, 2401 W Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Opin Drug Metab Toxicol 5:989-1004. 2009
    ....
  56. ncbi request reprint Correction of a saphenous vein graft to coronary vein anastamosis by selective retrograde coil-induced occlusion to arterialize the native vein
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Catheter Cardiovasc Interv 57:541-4. 2002
  57. doi request reprint The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients
    P A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Baltimore, MD 21215, USA
    J Thromb Haemost 8:43-53. 2010
    ..To study the effect of a new direct acting reversible P2Y(12) inhibitor, elinogrel (PRT060128), and the relation to cytochrome P450 (CYP) polymorphisms in patients with high platelet reactivity (HPR) on standard dual antiplatelet therapy...
  58. ncbi request reprint Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study
    Paul A Gurbel
    Sinai Hospital, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Avenue, Baltimore, MD, 21215, USA
    J Invasive Cardiol 14:584-9. 2002
    ..This finding may be related to superior scaffolding, resulting in a smoother luminal contour after implantation of a closed-cell stent...
  59. ncbi request reprint Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators
    V L Serebruany
    Union Memorial Hospital, Baltimore, MD, USA
    Stroke 29:235-8. 1998
    ..However, prospective data on the changes of platelet status in patients before the occurrence of hemorrhagic stroke after thrombolytic therapy are unavailable...
  60. ncbi request reprint The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    Rev Cardiovasc Med 7:S20-8. 2006
    ..This review explores the available information linking platelet reactivity during and after PCI to the occurrence of adverse events, including myocardial infarction, recurrent ischemia within 6 months, and stent thrombosis...
  61. ncbi request reprint Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries
    P A Gurbel
    Union Memorial Hospital and St Agnes Hospital, Baltimore, Maryland, USA
    J Am Coll Cardiol 31:1466-73. 1998
    ..We sought to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-III trial...
  62. ncbi request reprint Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor
    V L Serebruany
    Heart Associates Research and Education Foundation, Union Memorial Hospital, Baltimore, MD 21218, USA
    Prostaglandins Leukot Essent Fatty Acids 56:135-42. 1997
    ..Ability of Mg, diltiazem, and leumedins to favorably modulate plasma prostanoid levels have direct clinical implications for the use of these agents in patients with coronary artery disease...
  63. ncbi request reprint Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy
    V L Serebruany
    Center for Thrombosis Research, Sinai Hosital of Baltimore, MD 21215, USA
    Eur J Heart Fail 1:243-9. 1999
    ..However, no data are available on the plasma levels of Platelet/Endothelial Cell Adhesion Molecule-1 (PECAM-1), and platelet-derived osteonectin in this growing population...
  64. ncbi request reprint Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction
    P A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Scand Cardiovasc J 34:53-8. 2000
    ..634). The data suggest that the baseline characteristics predict future platelet activity, and may prospectively identify patients who will benefit most from antiplatelet strategies after coronary thrombolysis...
  65. ncbi request reprint Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction
    V L Serebruany
    Sinai Center for Thrombosis Research, Schapiro Research Building, Baltimore, Maryland 21215, USA
    J Thromb Thrombolysis 9:229-34. 2000
    ..The ability of MAC to favorably modulate the pre-reperfusion platelet status in such patients is of clinical importance, and further investigation in large-scale clinical trials seem warranted...
  66. ncbi request reprint Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department
    P A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 139:320-8. 2000
    ..Elevated P-selectin level also has been observed in the clinical setting of myocardial ischemia and reperfusion; however, its utility in differentiating cardiac from noncardiac origins of chest pain is unknown...
  67. ncbi request reprint Prasugrel
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Opin Investig Drugs 15:1627-33. 2006
    ..The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness...
  68. ncbi request reprint Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 136:398-405. 1998
    ..Platelets play an important role in the natural history of acute myocardial infarction (AMI)...
  69. ncbi request reprint Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department
    V L Serebruany
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, MD 21215, USA
    J Thromb Thrombolysis 11:155-62. 2001
    ..We sought to determine whether the combined measurement of platelet and necrosis markers would improve risk stratification, and yield higher diagnostic utility in patients presenting to the emergency department with chest pain...
  70. ncbi request reprint Soluble PECAM-1, but not P-selectin, nor osteonectin identify acute myocardial infarction in patients presenting with chest pain
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital of Baltimore, MD 21215, USA
    Cardiology 91:50-5. 1999
    ..Increased plasma PECAM-1 may serve as a useful marker in the early detection of patients with AMI. Larger studies will be necessary to confirm the utility of soluble PECAM-1 in identifying AMI among patients presenting with chest pain...
  71. ncbi request reprint Platelet function and fibrinolytic agents: two sides of a coin?
    K P Callahan
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Cardiology 95:55-60. 2001
    ..This review summarizes the latest and often confusing data on the interaction between fibrinolytic therapy and platelets in certain in vitro, animal and clinical scenarios...
  72. ncbi request reprint Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial)
    V L Serebruany
    Johns Hopkins University, Sinai Hospital, Baltimore, MD, USA
    Thromb Res 101:427-33. 2001
    ....
  73. ncbi request reprint Uniform platelet activation exists before coronary stent implantation despite aspirin therapy
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 142:611-6. 2001
    ..Enhanced platelet aggregation and receptor expression unquestionably occur after coronary stent implantation; however, the functional characteristics of platelets before stenting have not been fully elucidated...
  74. ncbi request reprint Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction
    V L Serebruany
    Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA
    Arterioscler Thromb Vasc Biol 19:153-8. 1999
    ..Further investigation of the possible role of PECAM-1 and the relationship between its soluble and platelet fractions in AMI are warranted...
  75. ncbi request reprint Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy)
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 146:91-8. 2003
    ..We measured platelet characteristics during chronic treatment in patients with coronary artery disease enrolled in the Roxifiban Oral Compound Kinetics Evaluation Trial (ROCKET-I)...
  76. ncbi request reprint Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors
    V L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Baltimore, MD, USA
    Pharmacol Res 43:453-62. 2001
    ..The documented anti-platelet effects of sertraline and NDMS may be directly related to the mortality benefits of SSRIs after ischemic events including myocardial infarction and stroke...
  77. ncbi request reprint Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 46:1705-9. 2005
    ..This study sought to determine the prevalence of platelet aspirin resistance using methods that directly indicate the degree of platelet cyclooxygenase inhibition...
  78. ncbi request reprint The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study
    Joseph DiChiara
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Diabetes 56:3014-9. 2007
    ..Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients...
  79. doi request reprint Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Platelets 21:360-7. 2010
    ..Further studies are required to investigate the primary mechanisms linking the above processes associated with a prothrombotic state resulting in clinical destabilization of the disease...
  80. ncbi request reprint Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry
    Victor L Serebruany
    Johns Hopkins University, Sinai Hospital, Baltimore, MD, USA
    Pathophysiol Haemost Thromb 32:8-15. 2002
    ..Taken together, opposite to our expectations, major clinical characteristics of heart failure did not correlate well with the platelet characteristics investigated in this study...
  81. ncbi request reprint Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients
    Joseph DiChiara
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Platelets 18:414-23. 2007
    ..These data suggest that VerifyNow may identify a generalized high platelet reactivity phenotype...
  82. ncbi request reprint Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Kevin P Bliden
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Am Coll Cardiol 49:657-66. 2007
    ....
  83. ncbi request reprint Platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    J Am Coll Cardiol 50:1822-34. 2007
    ....
  84. ncbi request reprint Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy
    Victor L Serebruany
    Sinai Hospital, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 145:636-42. 2003
    ..Therefore, the success of fibrinolytic therapy may be dependent on its direct effects on platelets...
  85. ncbi request reprint The role of platelet receptors and adhesion molecules in coronary artery disease
    Waiel M Samara
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Coron Artery Dis 14:65-79. 2003
    ..Moreover, knowledge of the mechanisms of cellular crosstalk will lead to important advances in the development of better antithrombotic therapies...
  86. ncbi request reprint The difference between clopidogrel responsiveness and posttreatment platelet reactivity
    Waiel M Samara
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Thromb Res 115:89-94. 2005
    ..However, patients responsive to clopidogrel may remain with highly reactive platelets and thus have increased thrombotic risk...
  87. ncbi request reprint The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy
    Anand Singla
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 158:784.e1-6. 2009
    ..However, the relation of platelet reactivity to glycemic control is less studied in patients on dual antiplatelet therapy...
  88. ncbi request reprint Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists
    Rolf P Kreutz
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Blood Coagul Fibrinolysis 18:713-8. 2007
    ..These findings support a pro-aggregatory state that, in part, explains the thrombotic events shown by epidemiological studies...
  89. ncbi request reprint Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction
    Raymond D Bahr
    St Agnes Hospital, Baltimore, Maryland, USA
    Am J Cardiol 90:310-2. 2002
  90. ncbi request reprint Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 143:1068-75. 2002
    ..We sought to determine whether platelet activity in patients with heart failure is related to an ischemic versus nonischemic etiologic condition, clinical disease severity, or adverse clinical outcomes...
  91. ncbi request reprint Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy
    V L Serebruany
    Emergency Departments and Critical Care Units, St Agnes and Union Memorial Hospitals, Baltimore, MD 21215, USA
    Cardiology 90:37-42. 1998
    ..Long-term aspirin therapy mildly reduces baseline platelet activity; however, this degree of relative platelet inhibition does not appear to be cardioprotective...
  92. ncbi request reprint Stent thrombosis: role of compliance and nonresponsiveness to antiplatelet therapy
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
    Rev Cardiovasc Med 8:S19-26. 2007
    ..Early identification of vulnerable patients and definition of the role of antiplatelet nonresponsiveness in the development of stent thrombosis should be the focus of future diagnostic and therapeutic strategies...
  93. ncbi request reprint Platelet monitoring for PCI: is it really necessary?
    U S Tantry
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Hamostaseologie 29:368-75. 2009
    ....
  94. ncbi request reprint Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy
    P A Gurbel
    Sinai Hospital, Baltimore, Maryland 21215, USA
    Am J Cardiol 87:774-7, A7. 2001
    ..A peak in soluble P-selectin levels at 3 hours after thrombolytic therapy and lower baseline platelet P-selectin were associated with successful thrombolysis...
  95. ncbi request reprint The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges
    V L Serebruany
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Thromb Res 96:51-6. 1999
    ..If P-selectin is to become a diagnostic tool for differentiating an etiology of chest pain, standardized measurements must be defined for each model of flow cytometer...
  96. doi request reprint Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies
    Richard C Becker
    Duke University School of Medicine, Durham, North Carolina, United States
    Thromb Haemost 103:535-44. 2010
    ..relevance of reversible and irreversible mechanisms of P2Y12 inhibition to bleeding risk, posing the question, "Is it not only how much but how a platelet P2Y12 receptor is inhibited that determines the attributable safety profile?"..
  97. ncbi request reprint [The role of clopidogrel in cardiovascular diseases]
    Paul A Gurbel
    Pol Arch Med Wewn 117:207-9. 2007
  98. ncbi request reprint Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4
    Wei C Lau
    Medical Director Cardiovascular Center Operating Rooms, Cardiovascular Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Pharm Res 23:2691-708. 2006
    ..Further investigation or guidelines are needed to optimize antiplatelet treatment strategies to identify and treat patients resistant to aspirin and/or clopidogrel...
  99. ncbi request reprint Clinical applications of antiplatelet therapy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Rev Cardiovasc Med 7:130-46; quiz 148-9. 2006
    ..Nonresponsiveness to clopidogrel treatment has been suggested as a risk factor for the occurrence of ischemic events and stent thrombosis...
  100. ncbi request reprint AZD6140
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA
    Expert Opin Investig Drugs 16:225-9. 2007
    ..It has fast onset and offset actions that may be advantageous in patients who may have to undergo immediate surgery...